Technology
Health
Pharmaceutical
Allena Pharmaceuticals
$7.229876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$7.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.38 (-5.00%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ALNA and other stocks, options, ETFs, and crypto commission-free!
About
Allena Pharmaceuticals, Inc. Common Stock, also called Allena Pharmaceuticals, is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Read More Its product pipeline includes Reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.
Employees
—
Headquarters
Newton, Massachusetts
Founded
2011
Market Cap
158.15M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
73.15K
High Today
$7.77
Low Today
$7.12
Open Price
$7.67
Volume
20.58K
52 Week High
$17.56
52 Week Low
$4.80
Collections
Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Therapy
2017 IPO
US
News
Seeking AlphaMar 13
Allena Pharmaceuticals (ALNA) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow
The following slide deck was published by Allena Pharmaceuticals, Inc. in conjunction with this event. 1 26 Click to enlarge Notes:...
MarketBeatMar 10
Stock Price, News, & Analysis for Allena Pharmaceuticals
News headlines about ALNA stock have trended somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Allena Pharmaceuticals earned a news impact score of 1.4 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10,...
Markets InsiderMar 7
Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
-- Achieved Alignment with U.S. Food and Drug Administration (FDA) on Phase 3 URIROXTM Program and Accelerated Approval Strategy for Reloxaliase -- -- Phase 3 URIROX-1 and URIROX-2 Trials Ongoing; URIROX-1 Topline Data Expected in Second Half of 2019 -- -- Louis Brenner, M.D. Appointed Chief Executive Officer -- -- Multiple Catalysts Expected Across Pipeline in 2019 -- NEWTON, Mass., March 07, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company...
Price Paid on Robinhood
20% Lower
Right Now
52 Week Low
$4.80
Average Price Paid
$9.00
52 Week High
$17.56
Earnings
-$0.58
-$0.51
-$0.45
-$0.38
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
-$0.46 per share